RE:$4.44 - Extremely Undervalued in Comparison to peersLet's go over the reasons we are so undervalued compared to other Phase 2 biotech companies. This is more for the Newbies to ARCH
1. Trading on the OTCQB and Toronto Venture Exchange (a lot of investors can't or won't buy on these exchanges)
2. They never took money from Wall St or Bay St so therefore no Wall St or Bay St analysts with Buy Recs on them.
3. No Liquidity to buy for any instiutional investors because of high Mgt/Insider and Friends and Family holdings approx 62%
4. They have kept an extremely low profile while progressing their drug thru P1 and P2. (This will change once they get into P3) The only big fanfare was when Canada Health announced they were funding P2 for Lungs, Zero coverage in the USA. Just wait how they will be touting when they fund P3
5. Management is focused on the data not promoting the stock (they know that will come when they get into P3)
There is more, please feel free to add to the above